NCT01901198View on ClinicalTrials.gov

Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

December 31, 2013

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.

Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0

BIOLOGICAL

Peginterferon 180 mcg single dose S.C.

Pegasys 180 mcg S.C. single dose on Day 0

Trial Locations (1)

100069

Beijing YouAn Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Beijing Bio-Fortune Ltd.

INDUSTRY

NCT01901198 - Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers | Biotech Hunter | Biotech Hunter